SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — May 24, 2012
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: May 24, 2012 · CIK: 0001213037 · Accession: 0001104659-12-039763
AI Filing Summary & Sentiment
File numbers found in text: 333-180810
Letter
Trovagene, Inc.
11055 Flintkote Avenue
San Diego, CA 92121
May 24, 2012
VIA EDGAR
United States Securities
and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Karen Ubell
Re: Trovagene, Inc.
Registration Statement on Form S-1
File No. 333-180810
Ladies and Gentlemen:
Trovagene, Inc. hereby respectfully requests the withdrawal of its request for acceleration dated May 22, 2012, of the effective date of the registration statement referred to above that was requested to become effective at 5:00 p.m., Washington D.C. time, on Thursday, May 24, 2012, or as soon thereafter as practicable.
TROVAGENE, INC.
By:
/s/ Antonius Schuh
Name:
Antonius Schuh
Title:
Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm Trovagene, Inc. 11055 Flintkote Avenue San Diego, CA 92121 May 24, 2012 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Karen Ubell Re: Trovagene, Inc. Registration Statement on Form S-1 File No. 333-180810 Ladies and Gentlemen: Trovagene, Inc. hereby respectfully requests the withdrawal of its request for acceleration dated May 22, 2012, of the effective date of the registration statement referred to above that was requested to become effective at 5:00 p.m., Washington D.C. time, on Thursday, May 24, 2012, or as soon thereafter as practicable. TROVAGENE, INC. By: /s/ Antonius Schuh Name: Antonius Schuh Title: Chief Executive Officer